Overview

A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy

Status:
Active, not recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to assess the efficacy of second and third line therapies (OFF vs. FOLFIRI) in a sequential cross-over design in patients pretreated with nab-paclitaxel/gemcitabine first line.

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborators:

Celgene
Celgene International II SARL